Navigation Links
Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
Date:6/21/2011

VANCOUVER, British Columbia, June 21, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 East Investment in Innovation Conference on Wednesday, June 22 at 12:15 AM EST. The conference is being held at the Hyatt Regency Hotel in Boston.

The IN3 East meeting, hosted by Elsevier, is a medtech industry forum and networking meeting. The meeting is designed to provide exposure and constructive interaction between emerging medical innovation companies like Enox Biopharma and both venture capitalists and large device manufacturers.

Dr. Rewcastle will present Enox's technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial. He will also review recently filed intellectual property that expands Enox's technology to cover the wound healing space.

"One of the most significant problems facing the worldwide medical establishment is hospital acquired infections. In the United States alone, these infections drain an estimated $30-45 billion dollars per year. Enox is uniquely positioned to address this problem with its antimicrobial technology which utilizes nitric oxide as the mechanism of action. Nitric oxide is an ideal antimicrobial agent as it is very effective but does not have resistance issues like antibiotics do."

"The IN3 East Conference represents a great opportunity," continued Rewcastle. "Enox will be attractive to both the venture capitalists and potential strategic partners in attendance. Our breakthrough technology has the potential of meeting the needs of hospitals worldwide who are currently underserved by existing infection prevention technology. I anticipate a positive response to our presentation and presence at this event."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices
2. PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015
3. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
4. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
5. Plato BioPharma, Inc Appoints New Board Member
6. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
7. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
8. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
9. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
10. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
11. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):